[go: up one dir, main page]

MXPA04001847A - Uso de sistemas de indan-1-ol polisbstituidos para producir drogas utilizadas en la profilaxis o tratamiento de la obesidad. - Google Patents

Uso de sistemas de indan-1-ol polisbstituidos para producir drogas utilizadas en la profilaxis o tratamiento de la obesidad.

Info

Publication number
MXPA04001847A
MXPA04001847A MXPA04001847A MXPA04001847A MXPA04001847A MX PA04001847 A MXPA04001847 A MX PA04001847A MX PA04001847 A MXPA04001847 A MX PA04001847A MX PA04001847 A MXPA04001847 A MX PA04001847A MX PA04001847 A MXPA04001847 A MX PA04001847A
Authority
MX
Mexico
Prior art keywords
prophylaxis
obesity
treatment
systems
drugs used
Prior art date
Application number
MXPA04001847A
Other languages
English (en)
Inventor
Bickel Martin
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of MXPA04001847A publication Critical patent/MXPA04001847A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invencion se relaciona con el uso de sistemas de indan-1-o1 polisubstituidos y las sales fisiologicamente aceptables y derivados fisiologicamente funcionales de los mismos para producir drogas utilizadas en la profilaxis o tratamiento de la obesidad. La invencion se relaciona con el uso de los compuestos de la formula (I), en donde los grupos se definen como se indica, y con las sales fisiologicamente aceptables y derivados fisiologicamente funcionales de los mismos para producir una droga utilizada en la profilaxis o tratamiento de la obesidad.
MXPA04001847A 2001-08-31 2002-08-17 Uso de sistemas de indan-1-ol polisbstituidos para producir drogas utilizadas en la profilaxis o tratamiento de la obesidad. MXPA04001847A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10142659A DE10142659A1 (de) 2001-08-31 2001-08-31 Verwendung von mehrfach substituierten Indan-1-ol. Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
PCT/EP2002/009200 WO2003020255A1 (de) 2001-08-31 2002-08-17 Verwendung von mehrfach substituierten indan-1-ol-systemen zur herstellung von medikamenten zur prophylaxe oder behandlung von obesitas

Publications (1)

Publication Number Publication Date
MXPA04001847A true MXPA04001847A (es) 2004-06-15

Family

ID=7697230

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04001847A MXPA04001847A (es) 2001-08-31 2002-08-17 Uso de sistemas de indan-1-ol polisbstituidos para producir drogas utilizadas en la profilaxis o tratamiento de la obesidad.

Country Status (10)

Country Link
US (3) US6686397B2 (es)
EP (1) EP1425000B1 (es)
JP (1) JP2005507382A (es)
AU (1) AU2002333447B2 (es)
CA (1) CA2458553A1 (es)
DE (1) DE10142659A1 (es)
IL (1) IL160600A0 (es)
MX (1) MXPA04001847A (es)
PE (1) PE20030363A1 (es)
WO (1) WO2003020255A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10142663B4 (de) 2001-08-31 2004-08-19 Aventis Pharma Deutschland Gmbh C2-Disubstituierte Indan-1-ol-Systeme
DE10142661B4 (de) * 2001-08-31 2004-06-09 Aventis Pharma Deutschland Gmbh Mehrfach substituierte Indan-1-ol-Systeme und ihre Verwendung als Arzneimittel
JP4774763B2 (ja) * 2004-03-25 2011-09-14 住友化学株式会社 精製酢酸３−メチル−２−ブテニルの製造方法
US20050238979A1 (en) * 2004-04-08 2005-10-27 Christophe Dumousseaux Compositions for application to the skin, to the lips, to the nails, and/or to hair
US20050257715A1 (en) * 2004-04-08 2005-11-24 Christophe Dumousseaux Compositions for application to the skin, to the lips, to the nails, and/or to hair
FR2876011B1 (fr) 2004-10-05 2006-12-29 Oreal Procede de maquillage d'un support et kit pour la mise en oeuvre de ce procede
EP1796505B1 (fr) * 2004-10-05 2009-09-09 L'Oréal Kit et procede de maquillage
US9649261B2 (en) 2004-10-05 2017-05-16 L'oreal Method of applying makeup to a surface and a kit for implementing such a method
KR100693528B1 (ko) * 2004-10-29 2007-03-14 주식회사 팬택 전원 지연 인가 기능을 가지는 무선통신 단말기
FR2888115B1 (fr) * 2005-07-08 2013-02-15 Oreal Fond de teint liquide, procede de maquillage et kit pour la mise en oeuvre d'un tel procede.
FR2889921B1 (fr) 2005-08-30 2007-12-28 Oreal Ensemble de conditionnement et d'application comportant un dispositif magnetique.
DE102013009631A1 (de) * 2013-06-10 2014-12-11 Forschungszentrum Jülich GmbH Verfahren zur Herstellung von Cathin

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2345146C3 (de) 1973-09-07 1981-08-06 Feinmechanische Werke Mainz Gmbh, 6500 Mainz Hydraulischer Stellantrieb
FR2345146A1 (fr) * 1976-03-23 1977-10-21 Logeais Labor Jacques Nouveau medicament a base d'(hydroxy-2 indanyl-2) 1-propanol
EP0009554B1 (de) 1978-07-27 1983-04-27 Schering Aktiengesellschaft Indanyl-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
DE3103372A1 (de) * 1981-01-27 1982-09-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Neue indanyl-derivate, ihre herstellung und verwendung
EP0874800B1 (en) * 1995-12-06 2003-08-06 Venantius Limited Indane dimer compounds with smooth muscle relaxing and/or mast cell stabilising and/or antiinflammatory activity
CA2241567A1 (en) 1996-01-17 1997-07-24 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
CA2264243C (en) 1996-08-30 2004-10-05 Novo Nordisk A/S Glp-1 derivatives
CN1190434C (zh) 1996-12-31 2005-02-23 雷迪实验室有限公司 新的杂环化合物、其制备方法和含有它们的药物组合物及其在治疗糖尿病和相关疾病中的应用
JP2001510195A (ja) 1997-07-16 2001-07-31 ノボ ノルディスク アクティーゼルスカブ 縮合化１，２，４−チアジアジン誘導体、その調製及び使用
US5987946A (en) 1997-08-15 1999-11-23 Watts; James A. Lock picking method and apparatus
FR2796070B1 (fr) * 1999-07-06 2003-02-21 Lipha Derives de benzodiazepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparation
EP1078632A1 (en) 1999-08-16 2001-02-28 Sanofi-Synthelabo Use of monoamine oxydase inhibitors for the manufacture of drugs intended for the treatment of obesity
RU2261860C2 (ru) * 2000-02-23 2005-10-10 Авентис Фарма Дойчланд Гмбх ЗАМЕЩЕННЫЕ В ПОЛОЖЕНИИ 8А ПРОИЗВОДНЫЕ 8,8А-ДИГИДРОИНДЕНО [1,2-d] ТИАЗОЛА, СПОСОБ ИХ ПОЛУЧЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ СРЕДСТВ, НАПРИМЕР В КАЧЕСТВЕ АНОРЕКСИЧЕСКИХ СРЕДСТВ
DE10142661B4 (de) * 2001-08-31 2004-06-09 Aventis Pharma Deutschland Gmbh Mehrfach substituierte Indan-1-ol-Systeme und ihre Verwendung als Arzneimittel
DE10142662B4 (de) * 2001-08-31 2004-07-08 Aventis Pharma Deutschland Gmbh Derivate von C2-substituierten Indan-1-ol-Systemen und ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
US6812256B2 (en) 2004-11-02
AU2002333447B2 (en) 2006-10-26
US6812257B2 (en) 2004-11-02
US20040106583A1 (en) 2004-06-03
EP1425000B1 (de) 2012-08-01
CA2458553A1 (en) 2003-03-13
EP1425000A1 (de) 2004-06-09
WO2003020255A1 (de) 2003-03-13
US20040092488A1 (en) 2004-05-13
US6686397B2 (en) 2004-02-03
US20030130323A1 (en) 2003-07-10
JP2005507382A (ja) 2005-03-17
PE20030363A1 (es) 2003-06-09
IL160600A0 (en) 2004-07-25
DE10142659A1 (de) 2003-03-20

Similar Documents

Publication Publication Date Title
UA102517C2 (ru) Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы
MY137039A (en) Thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof
AU2002218167A1 (en) N-phenyl-2-pyrimidine-amine derivatives
MY139303A (en) Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
MXPA04001847A (es) Uso de sistemas de indan-1-ol polisbstituidos para producir drogas utilizadas en la profilaxis o tratamiento de la obesidad.
DK1124841T3 (da) Substituerede phenylalkenoylguanidiner, fremgangsmåde til fremstilling deraf, anvendelse deraf som lægemidler eller diagnosemidler og lægemidler, som indeholder dem
DE59904180D1 (de) Cyclopentabenzofuran-derivate und ihre verwendung
IL166057A0 (en) Urea-substituted and urethane-substituted acylureas methods for the production thereof and their useas medicaments
ATE286894T1 (de) 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
PT1173176E (pt) Utilizacao de sistemas policiclicos de 2-amino-tiazole para a preparacao de medicamentos para a profilaxia ou tratamento da obesidade
PT1156805E (pt) Utilizacao de sistenas piliciclicos de tiazole para a fabricacao de medicamentospara a profilaxia ou o tratamento de obesidade
MY139613A (en) Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders
HK1049169B (zh) 取代的4-苄基氨基喹啉、其製備方法、含有這些化合物的藥物及其應用
PE20030236A1 (es) Derivados de bencimidazol 1-aril-2-n,s- u o-sustituidos, obtencion de medicamentos y preparados farmaceuticos que contienen estos derivados
CY1106129T1 (el) Κιταλοπραμη για την αγωγη της υψηλης πιεσεως του αιματος
IL160605A0 (en) Use of c2-substituted indan-1-ol systems for preparing medicaments for the prophylaxis or treatment of obesity
MXPA04001853A (es) Uso de sistemas de indan-1-ona c2-substituida para producir medicamentos para la profilaxis o tratamiento de obesidad.
MXPA04001858A (es) Uso de derivados de sistemas de indan-1-ol c2-substituidos para producir medicamentos para la profilaxis o el tratamiento de la obesidad.
MXPA04001854A (es) Sistema de indan-1-ol polisubstituidos, metodo para la produccion y uso de los mismos como drogas.
ATE374021T1 (de) Verwendung von l-azetylcarnitin zur herstellung eines medikaments zur präventiven post- chirurgischen schmerzbehandlung
IL160603A0 (en) C2-disubstituted indan-1-ol systems and their derivatives, processes for their preparation and their use as pharmaceuticals
MXPA03010920A (es) Uso de alconil l- carnitina para preparacion de medicamento para tratar anhedonia.
SE0202287D0 (sv) New compounds
AU2002359762A1 (en) Luminacin analogs and uses thereof

Legal Events

Date Code Title Description
HC Change of company name or juridical status
FG Grant or registration